Amyloid Imaging for Alzheimer's Disease in Practice

Slides:



Advertisements
Similar presentations
Corporate Strategy and Foreign Direct Investment
Advertisements

CHAPTER 20 CORPORATE STRATEGY AND FOREIGN DIRECT INVESTMENT.
Alzheimer’s Disease  Goals  To understand what dementia is  To explore causes, risk factors, symptoms, and treatments of Alzheimer’s Disease  To better.
Alabama Brief Cognitive Screener (ABCs)
The clinical research of early diagnosis and ultimately the treatment of Alzheimer’s disease 許一仁 董冠廷 詹鎮遠 陳柏廷.
Image from
Dementia Jaqueline Raetz, M.D.. Types of Dementia Alzheimer Dementia 70% Lewy Body Dementia about 22% Vascular Dementia 17% Frontotemporal Dementia Overall.
Volume 3, Issue 4, Pages (November 2017)
How to search effectively: Database searching and Refworks
Introduction to Direct-to-Consumer Genetic Testing
Perspectives on Managing Polycythemia Vera for the Nurse Practitioner and Physician Assistant.
Imaging AD Progression Amyloid Imaging Agents.
COPD by the Guidelines.
Introduction to Biosimilars
IL-12 and IL-23.
Improving the Diagnosis and Treatment of Seizures in Long-term Care
Program Goals Teriflunomide: Pooled Safety Data.
How to search effectively: database searching and RefWorks
Identifying and Managing Dyspnea Associated With CTEPH
Updates in Hodgkin Lymphoma
Best Practices in Huntington Disease
Modifying Disease Course in Alzheimer's Disease
Appropriate Stroke Prevention Strategies in Atrial Fibrillation
Diagnostic Algorithms for ACS and High-Sensitivity Troponin
Assessing and Modifying Risks for Older Drivers
The Role of Imaging in Diagnosing IPF Hands-On Case Studies
Early Dementia Distinguishing AD From MCI
Getting the Best out of Guidelines in the Rapidly Changing Landscape of RA Treatment.
Part II: It Takes a Team— Incorporating High-Sensitivity Troponin Into Clinical Care.
A Comprehensive Strategy Toward the Patient With Rhinorrhea
Reisa Sperling, Elizabeth Mormino, Keith Johnson  Neuron 
Counseling Patients About Germline BRCA Mutations
A Focus on Polycythemia Vera for Nurse Practitioners and Physician Assistants.
Improving Narcolepsy Diagnosis
Seizures in the Elderly: Treatment and Special Considerations
Diagnosing Nontuberculous Mycobacterial Disease
Improving Therapeutic Management of Huntington's Disease in Long-Term Care.
Guided by Objective Measures: Challenging Case Scenarios in Rheumatoid Arthritis.
Updated Guideline Recommendations for the Definitive Diagnosis of Unexplained Syncope.
Treating to Target in MS
شاید کتاب شما انتخاب شود
Introduction to AD. Practical Approaches to the Identification of Alzheimer Disease in Primary Care.
Program Goals Overview Is NEDA a Reasonable Target?
When Is Intrathecal Drug Delivery Appropriate?
Program Goals Disclaimers Defining Refractory Seizures.
NEDA 2-Year Endpoint: Not a Predictor of Long-Term Stability?
Current Challenges in Managing Hemophilia
Imaging to Assess IPF Progression A Case-Based Approach
Figure 1 Tau PET images in patients with Alzheimer disease
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups.
A Developmental Switch in Microglial HDAC Function
Evaluation Report Investigates a problem or a set of options.
Clinical Challenges and Updates in Managing Seizure Clusters
A Family Affair.
Prioritizing Prevention of HPV-Related Disease
Program Goals Overview Is NEDA a Reasonable Target?
Selecting Treatment Approaches in Hemophilia
When Is Intrathecal Drug Delivery Appropriate?
Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer
Evaluating the Science of Cardiogenic Shock
Unit 8: Course Summary.
Early Diagnosis and Management of SSc-ILD
Fig. 1. AD biomarker levels in the cerebrospinal fluid of iNPH, AD, and CN subjects. Box plots of Aβ42 (A), Aβ40 (B), Aβ42/Aβ40 ratio (C), t-tau (D),
Fig. 2. Correlation between Aβ42 and Aβ40 levels in iNPH, AD, and CN subjects. The scatter plot shows the correlation between Aβ42 and Aβ40 levels. Representative.
Detecting and Diagnosing Alzheimer’s Disease
Unit 6: Course Summary.
Figure 2 Aβ-PET scans obtained using different tracers
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER.
Understanding the Expanding Armamentarium for GIST
Evaluate the integral {image}
Presentation transcript:

Amyloid Imaging for Alzheimer's Disease in Practice

Disclosure

Program Goals

Introduction

Role of Aβ

Genetic Findings Support the Amyloid Hypothesis

Evolving Strategy for Evaluating Suspected Cognitive Impairment

Evolving Strategy for Evaluating Suspected Cognitive Impairment (cont)

Developing the Amyloid PET Appropriate Use Criteria

Appropriate Use Criteria: Preamble

Appropriate Use Criteria: Scenarios When Scanning Is Appropriate

Appropriate Use Criteria: Scenarios When Scanning Is Inappropriate

Applying the Criteria in Practice

Amyloid Imaging: Case Examples

Amyloid Imaging: Case Examples (cont)

Amyloid Imaging: Case Examples (cont)

Amyloid Imaging: Case Examples (cont)

Amyloid Imaging in Practice

Amyloid Imaging in Practice (cont)

Summary and Key Points

Abbreviations

References